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Alzheimer diseaseProtein phosphatase-2A (PP2A), an important phosphatase in dephosphorylating tau and preserving synapse, is
signiﬁcantly suppressed inAlzheimer's disease (AD), but themechanism is notwell understood. Here,we studied
whether phosphotyrosyl phosphatase activator (PTPA) could activate PP2A by reducing its inhibitory phosphoryla-
tion at tyrosine 307 (P-PP2AC). We found that overexpression of PTPA activated PP2A by decreasing the level of
P-PP2AC with reduced phosphorylation of tau, while knockdown of PTPA inhibited PP2A by increasing the level
of P-PP2AC with enhanced tau phosphorylation. We also observed that expression of PTPA could upregulate the
protein and mRNA levels of protein tyrosine phosphatase 1B (PTP1B) and simultaneous downregulation of
PTP1B eliminated PTPA-induced PP2A activation. Importantly, we also found that the protein level of PTPA is
downregulated in the brains of AD patients, and the AD transgenic mouse models with expression of mutant
human amyloid precursor protein (hAPP) or the longest human tau (htau), respectively. Our data indicate that
PTPA may activate PP2A through activating PTP1B and thus reducing the level of P-PP2AC, therefore upregulation
of PTPA may represent a potential strategy in rescuing PP2A and arresting tau pathology in AD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common neurodegenerative
disorder. Neuroﬁbrillary tangles (NFTs), which are mainly composed
of abnormally hyperphosphorylated tau, are one of pathologic hall-
marks in the brain of AD patients [1,2]. While the mechanisms leading
to the formation of the tangles are still elusive, an imbalance between
protein kinases and phosphatases has been well recognized as the
direct cause for the AD-like tau hyperphosphorylation [3]. PP2A accounts
for ~70% of total brain tau phosphatase activities and can dephosphory-
late tau isolated fromADbrains atmost of the hyperphosphorylated sites
[4]. The activity of PP2A in the AD brains is signiﬁcantly decreased [5,6].
Compared with other protein phosphatases, the negative correlation
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-in AD brains further supports the dominant role of PP2A in regulation of
tau phosphorylation [4–6]. Therefore, it is interesting to dissect the
mechanisms that regulate PP2A activity and restoring the activity of
PP2A might be a promising target for AD therapy.
PP2A, one of the four major classes (PP1, PP2A, PP2B, and PP2C) of
eukaryotic serine/threonine phosphoprotein phosphatases [7,8], is
existing as a holoenzymes. The core structure is composed of a 36 kDa
catalytic subunit (C subunit) and a constant 65 kDa structural subunit
(A subunit or PR65). The PP2A core enzyme associates with a variable
regulatory subunit (B subunit) to form the PP2A holoenzyme. It has
been reported that PP2A activity is modulated by either non-covalent
interactions with regulatory subunits [7], heat stable inhibitors or lipids
[9], or covalent post-translational modiﬁcations such as methylation
and phosphorylation [10–14]. For instance, methylation of PP2AC at
leucine-309, which is catalyzed by methyltransferase (PPMT1), leads to
PP2A activation; or unmethylation of PP2AC at leucine-309, which is
catalyzed by methylesterase (PME-1), leads to PP2A inactivation. Phos-
phorylation of PP2AC at tyrosine-307 (P-PP2AC), which is regulated by
PTP1B and Src, results in PP2A inhibition [15,16]. Moreover, we recently
demonstrated that activation of glycogen synthase kinase-3β (GSK-3β)
leads to inhibition of PP2A through accumulation of inhibitor-2 of PP2A
(I2PP2A) [17], increase of the level of P-PP2AC and reduction of PP2AC pro-
tein andmRNA levels [18], decreasing Leu309methylation by increasing
PME-1 protein level and decreasing PPMT1 protein level's and decreas-
ing PP2AB subunit protein level [19].
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(PTPA), which is initially known as the phosphotyrosyl phosphatase
activator. PTPA activates the phosphotyrosyl phosphatase activity of
the PP2A core enzyme in vitro [20], however, the mechanism by
which PTPA activates PP2A is still not well deﬁned. Human PTPA is
encoded by a single gene, mapped to chromosome 9q34 [21]. The tran-
scription gives rise to seven different splice variants, four of which are
active [22]. Basal expression of the gene is dependent on the ubiquitous
transcription factor Yin Yang1 [23] and functionally antagonized byp53
[24]. PTPA was found to be a highly conserved protein during evolution
[25,26] suggesting an important biological function for this protein.
However, it is unclear whether PTPA is involved in AD pathogenesis.
Since the phosphorylation of PP2AC at tyrosine-307 (P-PP2AC) in-
hibits the PP2A activity [14], we investigated in the present study
whether PTPA mediates the P-PP2AC and the underlying mecha-
nisms. We reported that PTPA mediates the activation of protein
phosphatase-2A through reducing the phosphorylation of PP2AC at
tyrosine-307 by protein tyrosine phosphatase 1B.Fig. 1. PTPA regulates tau phosphorylation. The expression of PTPA in HEK293/tau cells
pSUP-siPTPA (siPTPA), and pcDNA, pSUP and pSUP-siC (siC) were used as corresponding c
blotting (A, C, E, G) and quantitative analysis (B, D, F, H), respectively. The data were presen2. Materials and methods
2.1. Antibodies and regents
Polyclonal antibody (pAb) against PP2A catalytic subunit (PP2AC),
pAb against PP2A catalytic subunit phosphorylated at tyrosine-307
site (P-PP2AC) and monoclonal antibody (mAb) against Src were
purchased from Millipore (Billerica, MA), mAbs against PP2A
catalytic subunit methylated at leucine-309 site (M-PP2AC) and
demethylated at leucine-309 (DM-PP2AC) were purchased from
Millipore (Billerica, MA), pAbs against PTP1B, and GSK-3βwere pur-
chased from Abcam (Cambridge, MA). pAbs against phosphorylated at
serine 9 of GSK-3β (pS9-GSK-3β), phosphorylated at tyrosine 216 of
GSK-3β (pY216-GSK-3β), pAbs against phosphorylated tau at serine
214 (pS214), against phosphorylated tau at threonine 205 (pT205) or
231 (pT231), against phosphorylated tau at serine 396 (pS396), against
phosphorylated tau at serine 404 (pS404), mAbs against total tau
(tau-5) and nonphosphorylated tau at threonine 198/199/202 (tau-1)was manipulated genetically by transfection of wild type PTPA plasmid (wtPTPA) or
ontrols. The levels of PTPA protein or phosphorylated tau were measured by Western
ted as means±S.D. of three independent experiments; *, pb0.05, **, pb0.01 vs control.
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(PTPA) was purchased from Upstate (Lake Placid, NY), mAb DM1A
to α-tubulin was purchased from Sigma (St. Louis, MO). Cell culture
media were from Gibico (Grand Island, NY). Lipofectamine 2000 was
from Invitrogen (Carlsbad, CA). Okadaic acid was purchased from
Sigma (St. Louis, MO). Neurobasal and B27 were from Invitrogen
(Carlsbad, CA).
2.2. Construction of plasmids
To knock down PTPA in cells, shRNA oligo sequences were synthe-
sized as follows: 5′-AGCTTCGTTCCCTGTGATCCAGCACTTCAAGAGAGTG
CTGGATCACAGGGAACTTTTTTGGAAC-3′, 5′-TCGAGTTCCAAAAAAGTTCC
CTGTGATCCAGCACTCTCTTGAAGTGCTGGATCACAGGGAACGA-3′. As con-
trol, we used non-sense sequences: 5′-AGCTTCATACCGCTCAGTAGCG
ACATTCAAGAGATGTCGCTACTGAGCGGTATTTTTTTGGAAC-3′, 5′-TCGAGFig. 2. PTPA regulates PP2A activity with no effect on GSK-3β. The biochemical activity and th
overexpressed or knocked down in HEK293/tau cells. PP2A activity was measured by protein p
demethylated (DM-PP2AC), phosphorylated levels of PP2AC (P-PP2AC) (C–F), the total GSK-3
measured by Western blotting (C, E, G, I) and quantitative analysis (D, F, H, J), respectively. T
pb0.01 vs control.TTCCAAAAAAATACCGCTCAGTAGCGACATCTCTTGAA TGTCGCTACTGAGC
GGTATGA-3′ [27]. All were purchased as 64-nt ssDNA oligomers com-
posed of both forward and reverse sequences with 9-bp loop structures
and 3′ XholI and 5′ HindIII self-inactivating overhangs. Sense and anti-
sense oligomers (both at 20 μM) were incubated in annealing buffer for
3 min at 90 °C as described [28], then the temperature was lowered in
2 °C/min increments until 5 °C above their respective Tm and then
dropped to 4 °C at maximum ramp rates. Annealing shRNA was cloned
into pSUPER (pSUP), a mammalian expression vector that directs the
synthesis of siRNAs: pSUPER-siPTPA (pSUP-siPTPA) and pSUPER-siCon
(pSUP-siC).
pSilencer plasmid was purchased fromGeneChem Co., Ltd (Shanghai,
China), and sequences of PTP1B (5′-UAGGUACAGAGACGUCAGU-3′)
were selected to generate pSilencer constructs that produce small hairpin
RNA (shRNA), which was then spontaneously processed in vivo into
siRNA.e activity-dependent modiﬁcations of PP2A or GSK-3βwere measured when PTPA was
hosphatase activity assay (A and B). The levels of total PP2AC, the methylated (M-PP2AC),
β (t-GSK-3β) and the phosphorylated GSK-3β (pS9-GSK-3β, pT216-GSK-3β) (G–J) were
he data were presented as means±S.D. of three independent experiments; *, pb0.05, **,
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tion and cloned into the eukaryotic expression vector pcDNA3.1(+). All
plasmids were conﬁrmed by enzyme digestion and DNA sequencing.
2.3. Cell culture and transfection
The human embryonic kidney 293 (HEK293/tau) cells stably
transfected with the longest isoform of recombinant human tau
(tau441) were used for the study. HEK293/tau cells were cultured in
DMEM supplemented with 10% fetal bovine serum (FBS, GIBCO, MI) in
a humidiﬁed atmosphere of 5% CO2 in air at 37 °C. The cells were plated
into six-well plates overnight and plasmids were transfected the next
day using Lipofectamine 2000 according to the manufacturer's instruc-
tion (Invitrogen, CA).
The primary neurons from E18 rat hippocampus were seeded at
30,000–40,000 cells per well on 6-well chamber slides coated with
Poly-D-Lysine/Laminin (BD) in neurobasal medium supplemented with
2% B27/0.5 mM glutamine/25 mM glutamate. Half the culture medium
was changed every 3 days with neurobasal medium supplemented
with 2% B27 and 0.5 mM glutamine. All cultures were kept at 37 °C in
a humidiﬁed 5% CO2 containing atmosphere. More than 90% of the
cells were neurons after they were cultured for 7–17 days in vitro
(div); this was veriﬁed by positive staining for the neuronal speciﬁc
markers microtubule-associated protein-2 (MAP2, dendritic marker).
At 7 div, the neuron transfections were performed according to the
manufacturer's instruction (Invitrogen), and the ratio of the plasmids
to Lipofectamin 2000 was 1:2.
2.4. Western blotting and immunohistochemistry
For Western blotting, the cell or brain extracts were mixed with
sample buffer containing 50 mM Tris–HCl (pH 7.6), 2% SDS, 10% glyc-
erol, 10 mM dithiothreitol and 0.2% bromophenol blue and boiled for
5 min. Human tau transgenic mice (htau) and its littermate control
(endogenous tau knockout, tau−/−) were purchased from Jackson
Lab. The proteins were separated by 10% SDS-PAGE, transferred ontoFig. 3. OA reverses the PTPA-suppressed tau phosphorylation. HEK293/tau cellswere transfecte
OA (100 nM) for 4 h, levels of the hyperphosphorylated tau at multiple epitopes (A, B) and the
quantitative analysis, respectively. The data were presented as means±S.D. of three independthe nitrocellulose membrane and incubated with primary antibody at
4 °C overnight. Immune complexes were detected with appropriate
secondary antibodies and enhanced chemiluminescence (ECL) and
quantitatively analyzed by Kodak Digital Science 1D software (Eastman
Kodak Company, New Haven, CT). The relative intensity was expressed
as sum optical density.
For immunohistochemical studies, brain sections of AD patients
were gifts from Prof. Iqbal K (NYS Institute for Basic Research, Staten
Island,NY, USA). Sectionswere incubated at 4 °C overnightwith primary
antibodies. Immunoreaction was developed using HistostainTM-SP
kits and visualized with diaminobenizidine. The sections were observed
using a microscope (Olympus BX60, Tokyo). For immunoﬂuorescence,
cells were cultured on chamber slides. After various treatments, the
cells were ﬁxed for 40 min with 4% paraformaldehyde in PBS (pH 7.4)
and permeabilized for 10 min at room temperature in PBS containing
0.5% Triton X-100. Cells were blocked with 5% bovine serum albumin
(BSA) for 40 min, and further incubated with primary antibody at 4 °C
overnight, and then incubated for 1 h at 37 °C with Rhodamine Red-X-
or Oregon Green 488-conjugated secondary antibodies (1:1000; Molec-
ular Probes). Allﬂuorescence imageswere capturedwith a Zeiss LSM510
inverted ﬂuorescencemicroscope or a Zeiss LSM710 laser-scanning con-
focal ﬂuorescence microscope.
2.5. RT-PCR
Total RNAwas isolated using Trizol™ according to themanufacturer's
instruction (Invitrogen, CA). Then total RNA (3 μg in 25 μl) was reversely
transcribed and the produced cDNA (1 μl) was used to detect the tran-
scripts. For PTP1B, the following primers were used: 5′-GAGATTAC
TTTGTCCCGCTTAT-3′ (forward primer) and 5′-ATCCCTTCGTCCCTGTGG
-3′ (reverse primer). For GAPDH, 5′GAAGGTGAAGGTCGGAGTC3 ′ (for-
ward primer) and 5′GAAGATGGTGATGGGATTTC3 ′ (reverse primer)
were used. The PCR products were separated on 1.5% agarose gels and
stainedwith GoldView. The cDNA bandswere visualized under UV trans-
illumination andquantitatively analyzedusing softwareBioCaptMWV.10
(Vilber Lourmat, Marne-La-Vallee Cedex 1).dwithwild type PTPA plasmid (wtPTPA) or the vector (pcDNA) for 24 h, then treatedwith
phosphorylated levels of PP2AC (P-PP2AC) (C, D) were detected byWestern blotting and
ent experiments; **, pb0.01 vs pcDNA; #, pb0.05, ##, pb0.01 vswtPTPA.
Fig. 4. Knockdown of PTP1B abolishes PTPA-induced dephosphorylation of PP2AC at Tyr307. (A–E) HEK293/tau cells were transfected with wtPTPA or siPTP1B or the control vectors
in HEK293/tau cells for 48 h, and then the level and activity of PTP1B or Src were measured byWestern blotting (A, C), quantitative analysis (B, D), and chemical assay (E), DM1A as a
loading control. (F–G) HEK293/tau cells were co-transfected with wtPTPA and siPTP1B or siC for 48 h, then the levels of PTP1B, PTPA, PP2AC and P-PP2AC are measured by Western
blotting (F) and quantitative analysis (G-H), respectively. The data were presented as means±S.D. of three independent experiments; *, pb0.01, **, pb0.01 vs control or
wtPTPA+siC.
1239Y. Luo et al. / Biochimica et Biophysica Acta 1833 (2013) 1235–12432.6. Protein phosphatase and Src activity assay
To detect PP2A activity, the cell lysates were prepared by adding
phosphatase storage buffer (2 mM EGTA, 5 mM EDTA, 0.5 mM PMSF,
50 mM Tris–Cl (pH 7.4), 1:200 protease inhibitor cocktail) and endog-
enous phosphates was removed by using the Spin Column. The activity
of PP2A in the extract was assayed using a serine/threonine phosphatse
assay system (Promega, MA) according to the manufacturer's protocol.
The Src activity was measured by using a Src kinase assay kit
(GENMED SCIENTIFICS INC., Shanghai, China) according to the
manufacturer's instruction.
2.7. Statistical analysis
Datawere analyzedwith SPSS 13.0 statistical software. The one-way
analysis of variance procedure followed by least signiﬁcant difference
post hoc testswas used to determine the statistical signiﬁcance of differ-
ences of the means.3. Results
3.1. PTPA negatively regulates tau phosphorylation
To explore the effects of PTPA on tau phosphorylation,we transfected
pcDNA-PTPA or pSUP-siPTPA plasmid into HEK293/tau cells. We ﬁrst
measured the protein level of PTPA at 48 h after the transfection by
Western blotting. The levels of PTPA increased to ~368% when PTPA
was overexpressed (Fig. 1A and B), while the level of PTPA decreased
to ~41.5% of the control level after PTPA knockdown (Fig. 1C and D).
Overexpression of PTPA reduced signiﬁcantly the phosphorylation levels
of tau at Ser262 (pS262), Ser396 (pS396), Ser404 (pS404), Ser422
(pS422) and Ser198/199/202 (tau-1) sites (tau-1 antibody is speciﬁc
for tau dephosphorylated at this speciﬁc site and its increase suggests
the increased dephosphorylation at this site) (Fig. 1E and F). In contrast,
downregulation of PTPA dramatically enhanced tau phosphorylation at
the same sites (Fig. 1G and H). There was no signiﬁcant change of total
tau (tau-5). These data indicate that PTPA regulates tau phosphorylation.
Fig. 5. PTPA increases PTP1B transcription. The expression of PTPA in HEK293/tau cells was manipulated genetically by transfection of wtPTPA or pSUP-siPTPA (siPTPA), and pcDNA,
pSUP and pSUP-siC (siC) were used as controls. PTP1B mRNA level was detected by RT-PCR with GAPDH as a loading control. The data were presented as means±S.D. of three
independent experiments; **, pb0.01 vs control.
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PP2A is a crucial phosphatase in dephosphorylating tau, we there-
fore ﬁrst measured PP2A activity. We found that overexpression of
PTPA activated PP2A, whereas knockdown of PTPA inhibited PP2A
activity (Fig. 2A and B). Then, we investigated how PTPA regulates
PP2A activity. To this end, we detected the levels of methylation or
phosphorylation of PP2A catalytic subunit (PP2AC) because both of
these modiﬁcations modulate PP2A activity. We observed that the
inhibitory phosphorylation of PP2AC at tyrosine-307 (P-PP2AC) de-
creased signiﬁcantly in the cells overexpressing PTPA (Fig. 2C and D),
while the level of P-PP2AC increased in PTPA-depleted cells (Fig. 2EFig. 6. PTPA increases PTP1B and decreased pS396 in primary hippocampal neuron. The eGF
48 h, and then PTP1B (A) and tau phosphorylated at Ser396 site (pS396) (C) were detect
transfected neurons, and the data were presented as means±S.D of ~15 neurons with EGFand F). We also discovered that overexpression of PTPA increased the
levels of methylated PP2AC at leucine-309 (M-PP2AC, active form)
with reduction of the demethylated PP2AC (DM-PP2AC, inactive form)
(Fig. 2C and D). In contrast to PTPA overexpression, knockdown PTPA
had inverse effects on PP2AC methylation (Fig. 2E and F). The total
level of PP2AC was not changed. These results indicate that PTPA acti-
vates PP2A by regulatng the methylation and/or phosphorylation of
PP2AC.
Glycogen synthase kinase-3β (GSK-3β) is a key tau kinase [4,5],
GSK-3β also inhibits PP2A [17–19]. Thus, we studied whether PTPA
inﬂuences GSK-3β activity. We found that neither overexpression
nor knockdown of PTPA changed the levels of phospho-GSK-3β atP-labeled PTPA were transiently transfected into rat primary hippocampal neurons for
ed by immunoﬂuorescence staining and quantitative analysis (B, D). Arrows indicate
P out of ~180 neurons, respectively; **, pb0.01 vs control. Scale bar=20 μm.
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(Fig. 2G-J), indicating that PTPA does not affect GSK-3β.
To further verify whether PTPA decreases tau phosphorylation by
activation of PP2A,we treated PTPA expressing cellswith PP2A inhibitor
okadaic acid (OA) for 24 h. We observed that OA treatment attenuated
the PTPA-induced tau dephosphorylation at several sites with no obvi-
ous change in total tau level probed by R134d antibody (Fig. 3A and B).
We also found that, although PTPA overexpression decreased P-PP2AC,
P-PP2AC increased while combined with OA treatment (Fig. 3C and D).
3.3. PTPA modulates the phosphorylation of PP2AC by PTP1B
Since phosphorylation of tyrosine-307 is regulated by PTP1B
(a tyrosine phosphatase) and Src (a tyrosine kinase) [15,16], we
detected the levels of PTP1B and Src in cells with overexpression
or knockdown of PTPA. We found that overexpression of PTPA
increased the level of PTP1B (Fig. 4A–D), whereas knockdown of
PTPA decreased PTP1B level with no obvious changes in Src level
(Fig. 4A–D) or activity (Fig. 4E).
To further conﬁrm the involvement of PTP1B in dephosphorylation
of PP2AC at tyrosine-307, we used siRNA to knock down the level
of PTP1B. We observed that downregulation of PTP1B abolished the
PTPA-induced dephosphorylation of PP2AC (Fig. 4F and G). This re-
sult suggests that PTPA downregulates phosphorylation of PP2AC at
tyrosine-307 through upregulating PTP1B but not Src.
To explore the mechanisms underlying PTPA-induced upregulation
of PTP1B protein, we performed semi-quantitative PCR to measure the
mRNA levels of PTP1B.We found that overexpression of PTPA increased
the mRNA level of PTP1B, whereas knockdown of PTPA signiﬁcantly
decreased the level of PTP1B mRNA (Fig. 5A-D). These data indicate
that PTPA may increase PTP1B protein through upregulating mRNA
transcription.Fig. 7. PTPAprotein level decreases in brains of transgenicmice or ADpatient. (A–B) The level of
was measured byWestern blotting and quantitative analysis (n=4). (C–D) PTPA levels in the b
indicate immunostaining of PTPA in the neurons) and quantitative analysis (n=3). The data
pb0.01 vs tau−/−mice. Scale bar=50 μm.To conﬁrm the results, we did transiently transfected pcDNA-
PTPA into rat primary hippocampal neurons cultured for 7 days in
vitro (div). We also observed that neurons expressing PTPA in-
creased the immunostaining of PTP1B, and decreased immuno-
staining of pS396 compared with neurons expressing GFP control
(Fig. 6).
3.4. PTPA protein is decreased in transgenic mouse models and AD brain
To investigate whether PTPA is involved in AD pathogenesis, es-
pecially in tau phosphorylation, we detected the levels of PTPA
protein in the brains of 11 month-old tg2576 mice harboring the
human amyloid precursor protein 695 with Swedish double mutation
(hAPP) (HuAPP695; K670N/M671L, Jackson Lab), 11 month-old
human tau transgenic mice (hTau) (STOCK Mapttm1(EGFP)Klt Tg(MAPT)
8cPdav/J, Jackson Lab), and AD patients. We found that PTPA protein
was decreased dramatically in the brains of the transgenic mice and
AD patients, when compared with the age-matched controls (Fig. 7).
4. Discussion
PP2A is the most important phosphatase implication in dephos-
phorylating the abnormally hyperphosphorylated tau proteins isolated
from AD brains [29,30]. The activity of PP2A is signiﬁcantly suppressed
in brains of AD patients [5,6], but the upstream factors leading to
the inhibition of PP2A is not fully understood. Recently, we have
reported that activation of GSK-3β, a crucial tau kinase that is activated
in the AD brain, inhibits PP2A through upregulating I2PP2A [17], increas-
ing the inhibitory tyrosine-307 phosphorylation and decreasing the
expression of PP2A [18]. In the present study, we determine whether
PTPA regulates PP2A activity by detecting the phosphorylation
of PP2A at tyrosine-307, which inhibits PP2A activity. We observedPTPAprotein in 11 month-old non-transgenic (Wt), hAPP, htau or tau−/− transgenicmice
rain of AD patients or the controls were detected by immunohistochemistry (arrowheads
were presented as means±S.D. of three independent experiments; *, pb0.05 vs Wt, **,
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regulation of PTPA enhanced it. Together, these data indicate that
PTPA directly regulated PP2A activity through regulating the activity-
dependent phosphorylation of tyrosine-307.
PTPA, a ubiquitous [31] and highly conserved protein [26], is ﬁrst
named as phosphotyrosyl phosphatase activator. Previous in vitro
study has reported that PTPA has peptidyl prolyl cis/trans-isomerase
(PPIase) activity and regulates the isomerization of Pro-190 on
human PP2AC, therefore activating PP2A [32]. Additional study has
demonstrated that the interaction of PTPA with hetero-dimeric
PP2A A-C results in activation and alteration of substrate speciﬁcity
of PP2A [33]. Moreover, recent studies have reported that PTPA can
physiologically function to reactivate the inactive form of PP2A
(PP2Ai) [34–36], which binds to PME-1 to form a stable complex.
This ﬁnding led to the renaming of PTPA as the PP2A phosphatase
activator.
In the present study, we showed that genetic upregulation of PTPA
level increased PP2A methylated at leucine-309. We also found that
over expression of PTPA can reduce tau phosphorylation, indicating
that PTPA positively regulates PP2A Ser/Thr activity. Moreover, we
ﬁrstly discovered that PTPA activates PP2A activity by decreasing
the level of PP2A phosphorylated at tyrosine-307.
To explore the molecule(s) that may mediate the effects of
PTPA on PP2A phosphorylation at tyrosine-307, we detected the
level of PTP1B, the ﬁrst puriﬁed protein tyrosine phosphatase that
can dephosphorylate PP2A at tyrosine-307 [37]. We found that
upregulation of PTPA increased the protein and mRNA levels of
PTP1B. Furthermore, knockdown of PTP1B by siRNA almost
abolished the PTPA-induced PP2A dephosphorylation. These data
strongly suggest that PTPA may regulate the tyrosine phosphoryla-
tion of PP2A through PTP1B. A previous study also demonstrated
that overexpression of PTP1B enhanced PP2A activity via decreasing
the level of phosphorylated PP2AC at tyrosine-307 [38]. Previous
studies have shown that Src, a tyrosine kinase, can phosphorylate
PP2AC at tyrosine-307, and thus inhibit PP2A activity [38,39]. There-
fore, we also investigated whether Src is involved in the
PTPA-induced PP2A dephoshorylation at tyrosine-307. We found
that either the protein level or the activity of Src was not changed
by PTPA.
PTPA induced cell apoptosis in HCT116 human colorectal carci-
noma and the OK opossum kidney cell lines [40]. Incubation of
cells with the PP2A inhibitor okadaic acid does not prevent PTPA-
induced apoptosis, indicating that PTPA is unlikely to mediate its
proapoptotic effect via PP2A [40]. PTP1B is a negative regulator of
tyrosine kinase growth factor signaling, overexpression of PTP1B
induced brown adipocyte, chondrocytes and hepatocyte apoptosis
[41–43]. In the present study, we were surprised to ﬁnd that
overexpression of PTPA has no effect on the viability of HEK293/
tau cells (Fig. S1), the mechanism needs further investigation.
Finally, to understand the pathological signiﬁcance of PTPA in
AD pathogenesis, we found that the levels of PTPA are decreased
in the brains of hAPP, htau transgenic mice and AD patient. Taken
together, we have demonstrated in the present study that PTPA
enhanced PP2A activity through reducing the phosphorylation
of PP2AC at tyrosine-307 by PTP1B. Moreover, downregulation of
PTPA might be partially responsible for PP2A suppression, and
therefore contributes to tau phosphrylation in AD pathogenesis.
Restoration of PTPA in AD brains may result in activation of PP2A,
which may represent a powerful strategy in preventing/reversing tau
hyperphosphorylation and accumulation.Conﬂicts of interest statement
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